Business Description
Vericel Corp
NAICS : 541715
SIC : 2836
ISIN : US92346J1088
Total Employee Number:
398Description
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.54 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.27 | |||||
Debt-to-EBITDA | 2.97 | |||||
Interest Coverage | 24.76 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 11.27 | |||||
Beneish M-Score | -2.48 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15 | |||||
3-Year FCF Growth Rate | 30.4 | |||||
3-Year Book Growth Rate | 19.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 64.63 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 17.81 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 79.12 | |||||
9-Day RSI | 78.23 | |||||
14-Day RSI | 76.04 | |||||
3-1 Month Momentum % | 5.76 | |||||
6-1 Month Momentum % | -5.77 | |||||
12-1 Month Momentum % | -15.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.18 | |||||
Quick Ratio | 4.79 | |||||
Cash Ratio | 3.08 | |||||
Days Inventory | 87.41 | |||||
Days Sales Outstanding | 83.63 | |||||
Days Payable | 79.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | -0.22 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.84 | |||||
Operating Margin % | 5.4 | |||||
Net Margin % | 7.35 | |||||
EBITDA Margin % | 10.89 | |||||
FCF Margin % | 16.22 | |||||
OCF Margin % | 21.1 | |||||
ROE % | 6.56 | |||||
ROA % | 4.69 | |||||
ROIC % | 5.16 | |||||
3-Year ROIIC % | 13.84 | |||||
ROC (Joel Greenblatt) % | 9.68 | |||||
ROCE % | 5.56 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 111.86 | |||||
Forward PE Ratio | 95.61 | |||||
PE Ratio without NRI | 111.86 | |||||
PS Ratio | 8.52 | |||||
PB Ratio | 6.73 | |||||
Price-to-Tangible-Book | 6.83 | |||||
Price-to-Free-Cash-Flow | 52.37 | |||||
Price-to-Operating-Cash-Flow | 40.12 | |||||
EV-to-EBIT | 102.29 | |||||
EV-to-EBITDA | 73.81 | |||||
EV-to-Revenue | 8.04 | |||||
EV-to-Forward-Revenue | 7.09 | |||||
EV-to-FCF | 49.45 | |||||
Price-to-GF-Value | 0.86 | |||||
Price-to-Projected-FCF | 5.04 | |||||
Price-to-Median-PS-Value | 1.08 | |||||
Price-to-Graham-Number | 5.83 | |||||
| Price-to-Net-Current-Asset-Value | 20.92 | |||||
| Price-to-Net-Cash | 151.85 | |||||
Earnings Yield (Greenblatt) % | 0.98 | |||||
FCF Yield % | 1.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vericel Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 250.882 | ||
| EPS (TTM) (€) | 0.356 | ||
| Beta | 0.2791 | ||
| 3-Year Sharpe Ratio | 0.23 | ||
| 3-Year Sortino Ratio | 0.39 | ||
| Volatility % | 49.8 | ||
| 14-Day RSI | 76.04 | ||
| 14-Day ATR (€) | 0.911483 | ||
| 20-Day SMA (€) | 35.19 | ||
| 12-1 Month Momentum % | -15.52 | ||
| 52-Week Range (€) | 25.4 - 41 | ||
| Shares Outstanding (Mil) | 51.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vericel Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vericel Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 125 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 124 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-31 08:30 | In 27 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 26 days | ||
| Guidance call for 2026 | 2026-06-16 11:20 | 32.40 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 31.40 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 31.40 (+0.00%) | ||
| General meeting for 2026 | 2026-04-29 09:00 | 31.20 (+0.00%) | ||
| Guidance call for 2026 | 2026-03-10 08:40 | 28.60 (+0.00%) | ||
| TD Cowen 46th Annual Healthcare Conference | 2026-03-04 09:50 | 29.80 (+0.00%) |
Show
Entries
Vericel Corp Frequently Asked Questions
What is Vericel Corp(FRA:ATQP)'s stock price today?
The current price of FRA:ATQP is €41.00. The 52 week high of FRA:ATQP is €41.00 and 52 week low is €25.40.
When is next earnings date of Vericel Corp(FRA:ATQP)?
The next earnings date of Vericel Corp(FRA:ATQP) is 2026-07-31 Est..
Does Vericel Corp(FRA:ATQP) pay dividends? If so, how much?
Vericel Corp(FRA:ATQP) does not pay dividend.
Press Release
Articles on Vericel Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers